Elite in Neurofibromatosis Type 1 (NF1)

Dr. Scott R. Plotkin

Neurology
55 Fruit Street, Yawkey Center For Outpatient Care, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Elite in Neurofibromatosis Type 1 (NF1)
55 Fruit Street, Yawkey Center For Outpatient Care, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Plotkin is a Neurologist in Boston, Massachusetts. Dr. Plotkin is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis, and Acoustic Neuroma. Dr. Plotkin is currently accepting new patients.

His clinical research consists of co-authoring 185 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 57 articles and participated in 1 clinical trial in the study of Neurofibromatosis Type 1 (NF1).

Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Massachusetts General Hospital
Massachusetts Eye And Ear Infirmary -
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Mass General Brigham Cancer Institute: Neuro-Oncology
55 Fruit Street, Yawkey Center For Outpatient Care, Boston, MA 02114

Additional Areas of Focus

Dr. Plotkin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas
Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas
Enrollment Status: Recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 2
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Binimetinib
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Tanezumab
Study Phase: Phase 2
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Enrollment Status: Terminated
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation
A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation
Enrollment Status: Unknown
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drug: AZD2014
Study Phase: Phase 2
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Device
Study Phase: Not Applicable
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Enrollment Status: Completed
Publish Date: February 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Enrollment Status: Completed
Publish Date: January 12, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype
Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Behavioral
Study Phase: Not Applicable
View 11 Less Clinical Trials

185 Total Publications

Medical therapy for vestibular schwannoma.
Medical therapy for vestibular schwannoma.
Journal: Handbook of clinical neurology
Published: October 06, 2025
Similar Doctors
Elite in Neurofibromatosis Type 1 (NF1)
Dr. Justin Jordan
Neurology
Elite in Neurofibromatosis Type 1 (NF1)
Dr. Justin Jordan
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Jordan is a Neurologist in Boston, Massachusetts. Dr. Jordan is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Schwannomatosis, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Neurofibromatosis Type 2 (NF2).

Elite in Neurofibromatosis Type 1 (NF1)
Dr. Nicole Ullrich
Pediatric Neurology | Neurology
Elite in Neurofibromatosis Type 1 (NF1)
Dr. Nicole Ullrich
Pediatric Neurology | Neurology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
617-632-3586
Languages Spoken:
English
See accepted insurances

Nicole Ullrich is a Pediatric Neurologist and a Neurologist in Boston, Massachusetts. Dr. Ullrich is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Optic Glioma.

Distinguished in Neurofibromatosis Type 1 (NF1)
Dr. Kien-ninh Ly
Neurology | Oncology
Distinguished in Neurofibromatosis Type 1 (NF1)
Dr. Kien-ninh Ly
Neurology | Oncology
Pappas Center For Neuro-oncology, Yawkey 9e, 55 Fruit Street, 
Boston, MA 
 (0.1 miles away)
617-724-8770
Languages Spoken:
English
See accepted insurances

Kien-ninh Ly is a Neurologist and an Oncologist in Boston, Massachusetts. Dr. Ly is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Brain Tumor, and Pediatric Low-Grade Glioma (pLGG).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Plotkin's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 15 Distinguished Conditions
View All 14 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile